Michael Schmitz
Stock Analyst at Guggenheim
(2.98)
# 1,364
Out of 5,113 analysts
7
Total ratings
100%
Success rate
56.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $9.96 | -49.80% | 1 | Nov 14, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $33.88 | +26.92% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $44.27 | +1.65% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $117.63 | -30.29% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $12.89 | +210.32% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.21 | - | 1 | Jan 3, 2023 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $9.96
Upside: -49.80%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $33.88
Upside: +26.92%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $44.27
Upside: +1.65%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $117.63
Upside: -30.29%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $12.89
Upside: +210.32%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -